logo
#

Latest news with #ELVN

Enliven Therapeutics, Inc. (ELVN) Backed by Goldman Sachs After Strong Trial Data
Enliven Therapeutics, Inc. (ELVN) Backed by Goldman Sachs After Strong Trial Data

Yahoo

time17-06-2025

  • Business
  • Yahoo

Enliven Therapeutics, Inc. (ELVN) Backed by Goldman Sachs After Strong Trial Data

Enliven Therapeutics, Inc. (NASDAQ:ELVN) is among the best NASDAQ stocks under $50 to buy. On Monday, analysts at Goldman Sachs started coverage on Enliven Therapeutics, Inc. (NASDAQ:ELVN) with a Buy rating and a $37.00 price target, implying a rise of about 60% from the current levels. The firm's confidence in the stock stems from favorable Phase 1 data for the company's chronic myeloid leukemia (CML) solution. The investment bank noted that ELVN-001's sustained efficacy data, presented during the European Hematology Association meeting, highlighted a 47% overall cumulative major molecular response (MMR) rate by 24 weeks and a 41% response in tyrosine kinase inhibitor (TKI)-resistant patients. These results surpassed the fourth-generation Scemblix by Novartis (SIX:NOVN) figures, with a difference of 10% and 32%, respectively. A biologist in a laboratory examining a microscope for small molecule inhibitors. The company is all set to launch a Phase 3 trial in 2026, which in itself is a $3 billion opportunity. If we look at the three-year return, Enliven Therapeutics, Inc. (NASDAQ:ELVN) exhibited a return of a whopping 1,980.18% in contrast to the 64.53% return by the market. Calling this simply an 'amazing' performance would be an understatement. Enliven Therapeutics, Inc. (NASDAQ:ELVN), headquartered in Boulder, Colorado, is a clinical-stage biopharmaceutical company. The company focuses on the recognition and development of small-molecule inhibitors to assist people living with cancer, improving survival and overall well-being. While we acknowledge the potential of ELVN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None.

Enliven price target lowered to $27 from $36 at JonesResearch
Enliven price target lowered to $27 from $36 at JonesResearch

Yahoo

time17-05-2025

  • Business
  • Yahoo

Enliven price target lowered to $27 from $36 at JonesResearch

JonesResearch analyst Soumit Roy lowered the firm's price target on Enliven (ELVN) to $27 from $36 and keeps a Buy rating on the shares. The company's abstract from the Phase 1 late line chronic myeloid leukemia trial with ELVN-001 'was met with a lukewarm initial stock reaction that weakened over time,' the analyst tells investors in a research note. The firm says that even though ELVN-001 showed efficacy and safety profile inline with the September 2024 update with two-times the patient population, the market treated the stock with a sell on news approach. Jones sees ELVN-001 performing at least inline with Novartis' Scemblix. Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See Insiders' Hot Stocks on TipRanks >> Read More on ELVN: Disclaimer & DisclosureReport an Issue Enliven Therapeutics' ELVN-001: Promising Competitor in the $3 Billion Late Line CML Market Enliven Therapeutics Reports Q1 Results and Pipeline Progress Enliven price target raised to $40 from $39 at H.C. Wainwright Enliven Therapeutics: Strategic Focus and Promising Developments Justify Buy Rating Positive Buy Rating for Enliven Therapeutics Driven by Promising Phase 1 Results of ELVN-001 in CML Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store